Information on the total number of voting rights and shares

 

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares on 9 January 2019 following the conversion of convertible bonds issued on the private placement on 7 March 2018. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on regulated market.

Total amount of share capital on 12 December 2018

EUR 12,531,512

Total number of shares with voting rights on 12 December 2018

8,310,546

Total number of new shares issued on 9 January 2019

31,606

 

Total amount of share capital on 9 January 2019

EUR 12,579,237

Total number of shares with voting rights on 9 January 2019

8,342,152 (a)

Total number of voting rights (denominator) on 9 January 2019

8,342,152

Total number of attributed warrants

167,300

Total number of convertible bonds outstanding

253

Total number of bond warrants outstanding

2,070

Total number of shares with voting rights following the exercise of the bond warrants, the conversion of the convertible bonds and the attributed warrants (1)

1,507,070 (b)

Total number of diluted shares

9,849,222 (a+b)

 

(1) Based on the conversion price of EUR 4.3347 (92% of the Volume-Weighted-Averaged-Price of Bone Therapeutics on 9 January 2019)


In addition, the Company also announces that a listing prospectus has been prepared following the creation of more than 20% of new shares due to bond conversions since the private placement of convertible bonds in March 2018.

The listing prospectus was approved by the Belgian Financial Services and Markets Authority (the "FSMA") on 27 December 2018, and subsequently notified to the French Financial Markets Authority (Autorité des Marchés Financiers, the "AMF").

The listing prospectus and related documents are available on Company’s website.

Note

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

The Company’s primary clinical focus is ALLOB, an allogeneic “off-the-shelf” cell therapy platform derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. In addition, the Company also has JTA-004, a viscosupplement in development for the treatment of knee osteoarthritis.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.

Interested in a regular update of the Life Sciences and biotech sector in Flanders?